TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07712380: A Randomized, Observer-blind, Placebo-controlled Exploratory Study to Evaluate Whether Administration of Adjuvanted RZV or RSVPreF3 Vaccine Can Attenuate Coronary Plaque Progression in Individuals 50 Years of Age and Abo

Sponsor: GlaxoSmithKline · Phase: PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 450 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$16,480,000

Rescue Site Savings

+$10,866,500

Unlock Full NCT07712380 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07712380 Rescue Dossier →